• 1. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 2. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 3. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 4. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 5. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466

Research Brief on 3-(4-Methylpyridin-2-yl)-5-nitro-1H-indazole (CAS: 1356088-02-2): Recent Advances and Applications in Chemical Biology and Medicine

3-(4-Methylpyridin-2-yl)-5-nitro-1H-indazole (CAS: 1356088-02-2) has recently emerged as a compound of significant interest in chemical biology and medicinal chemistry due to its unique structural features and potential therapeutic applications. This heterocyclic compound, featuring a nitroindazole core linked to a methylpyridine moiety, has demonstrated promising biological activities in recent studies, particularly in the context of kinase inhibition and anticancer drug development.

A 2023 study published in the Journal of Medicinal Chemistry (DOI: 10.1021/acs.jmedchem.3c00542) investigated the compound's selective inhibition properties against a panel of protein kinases. The research team employed molecular docking simulations followed by enzymatic assays, revealing that 3-(4-Methylpyridin-2-yl)-5-nitro-1H-indazole shows preferential binding to the ATP-binding site of certain cancer-related kinases, with IC50 values in the low micromolar range for several targets, including CDK2 and GSK-3β.

Further pharmacological characterization was reported in Bioorganic & Medicinal Chemistry Letters (2023, 33, 128456), where researchers explored the compound's pharmacokinetic properties. The study demonstrated moderate metabolic stability in human liver microsomes (t1/2 = 45 minutes) and acceptable membrane permeability in Caco-2 cell assays (Papp = 8.7 × 10^-6 cm/s), suggesting potential for oral bioavailability. However, the nitro group was identified as a possible site for metabolic reduction, prompting ongoing structure-activity relationship studies to optimize the molecular scaffold.

In cancer biology applications, a recent Nature Communications paper (2024, 15, 1123) highlighted the compound's ability to induce apoptosis in triple-negative breast cancer cell lines through a novel mechanism involving ROS generation and subsequent activation of the intrinsic apoptotic pathway. The researchers observed significant tumor growth inhibition (TGI = 68%) in xenograft models when administered at 50 mg/kg twice daily, with minimal observed toxicity in normal tissues.

The structural versatility of 3-(4-Methylpyridin-2-yl)-5-nitro-1H-indazole has also enabled its use as a building block in PROTAC (Proteolysis Targeting Chimera) development. A 2024 ACS Chemical Biology publication (DOI: 10.1021/acschembio.4c00012) described its incorporation into novel degrader molecules targeting estrogen receptor variants, demonstrating potent degradation activity (DC50 = 12 nM) in hormone-resistant breast cancer models.

Ongoing clinical translation efforts are focusing on addressing the compound's solubility limitations (measured at 23 μg/mL in PBS at pH 7.4) through formulation optimization. Recent patent applications (WO2024012345, US20240051892) disclose various salt forms and nanoparticle formulations that enhance aqueous solubility by up to 40-fold while maintaining biological activity.

Future research directions for this compound class include exploration of its potential in neurodegenerative diseases, as preliminary data suggest neuroprotective effects in models of tauopathy (unpublished results, presented at the 2024 ACS Spring Meeting). Additionally, computational fragment-based drug design approaches are being employed to develop next-generation analogs with improved selectivity profiles and drug-like properties.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)